Wake Forest University Health Sciences

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Wake Forest University Health Sciences sits in the top decile of US sponsors by registered trial count (#27 of 15,742 sponsors by registered trial count).

1,140 total trials 174 currently recruiting 724 completed early-phase tilt top decile by trial count

Wake Forest University Health Sciences: 1,140 sponsored US clinical trials, 174 recruiting.

Wake Forest University Health Sciences sponsors 1,140 registered US clinical trials on ClinicalTrials.gov, 174 of them currently recruiting, and 724 completed. 111 of these trials are in Phase 3-4 (later-stage) and 239 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 9 trials.

Top-decile sponsor footprint

Wake Forest University Health Sciences ranks in the top decile of sponsors by registered trial count (#27 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 44/100

724 of 885 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,140 total, page 15 of 23

COMPLETED NA

Programs To Support You During Chemotherapy

NCT02489422

COMPLETED NA

Assessing the Feasibility of the Use of Visual Aids in Patient Education in Adults With Down Syndrome (DS)

NCT02895802

TERMINATED NA

Resection Versus Microwave Ablation for Resectable Colorectal Cancer Liver Metastases

NCT02866344

COMPLETED NA

Comprehensive Post-Acute Stroke Services

NCT02588664

COMPLETED NA

Pre-hospital Advanced Therapies for Control of Hemorrhage - Pelvis

NCT02855060

COMPLETED Phase 2

Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer

NCT02581943

TERMINATED Phase 4

Predicting, Understanding and Speeding Recovery After TKA

NCT02685735

COMPLETED NA

Family-Centered Cesarean Delivery

NCT02690077

COMPLETED NA

Vitamin D Deficiency and Dysautonomia

NCT03032328

TERMINATED NA

Effect of Mentoring on Endotracheal Tube Exchange Using a New Device

NCT02763189

TERMINATED NA

Tourniquet Pressure in Primary Total Knee Arthroplasty

NCT02830087

COMPLETED NA

Pain Effect on Attention Using an Ipad Game App

NCT03115788

COMPLETED

Changes in Circulating Tumor-Specific DNA in Patients With Non-Metastatic Non-Small Cell Lung Cancer

NCT03746262

COMPLETED Phase 4

Internet Surveys and Their Impact on Adherence for Rosacea

NCT03048058

COMPLETED NA

Palliative Radiation Therapy in Reducing Pain in Patients With Bone Metastasis

NCT02699697

COMPLETED

Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors

NCT02747407

COMPLETED NA

Power Morcellation Systems for Laparoscopic Hysterectomy and Myomectomy

NCT02777203

COMPLETED NA

Psychosocial Stress and Aging in HIV

NCT02965469

COMPLETED

Bedside Ultrasound to Measure Optic Nerve Sheath Diameter in Pediatric CSF Shunts

NCT02776085

COMPLETED Phase 2

Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer

NCT02581982

COMPLETED NA

Prehabilitation Using Aquatic Exercise

NCT02773745

COMPLETED Phase 2

Intranasal Insulin and Post-stroke Cognition: A Pilot Study

NCT02810392

COMPLETED NA

Oral Psoriasis Treatment Adherence and Intervention Study

NCT02850900

COMPLETED Phase 3

Analgesic Benefit of PECS Blocks for Biceps Tenodesis Shoulder Surgery

NCT02741713

TERMINATED NA

Lutonix or Inpact for tHE tReatment Of fEmeropopliteal Stenosis - Drug Coated Balloon

NCT02812966

TERMINATED Phase 2

Efficacy of Ginseng for Patients on Regorafenib

NCT02581059

COMPLETED Phase 1

Muscadine Grape Skin Extract in Treating Patients With Malignancy That Is Metastatic or Cannot Be Removed by Surgery

NCT02583269

COMPLETED NA

Assessment of Infection Control, Practice Efficiency, and Health Economics of Sheathed Versus Standard Cystoscopy

NCT02922868

COMPLETED NA

The Efficacy of Cranial Electrostimulating Therapy for Depression and Anxiety Among Homeless Adults

NCT02732561

TERMINATED NA

TAE and MWA Combination Therapy in Early-stage Hepatocellular Carcinoma

NCT02704130

TERMINATED NA

Video vs. Direct Laryngoscopy in Pediatric Nasal Intubation

NCT03032263

TERMINATED NA

Community Hospital Identification of High CV Risk Patients During Cancer Treatment

NCT02566109

COMPLETED NA

Aiming to Improve Readmissions Through InteGrated Hospital Transitions

NCT02763202

COMPLETED NA

Dietary Acid Load, Kidney Function and Disability in Elderly

NCT02691663

COMPLETED Phase 4

A Pilot Study Comparing Anti-Inflammatory Effects Of TXA Versus EACA In Pediatric Congenital Heart Surgery

NCT02656472

TERMINATED NA

Take the Fight in Supporting and Empowering Patients With Cancer

NCT02729883

COMPLETED NA

An Evaluation Of The Novel TRAMINER Sequence By Comparison To Late Gadolinium Enhancement Images

NCT02727725

COMPLETED

Attitudes and Knowledge Regarding Clinical Trials in Underserved Populations Receiving Care at the Comprehensive Cancer Center of Wake Forest University

NCT02444754

TERMINATED NA

Controlled Trial to Compare Single Versus Two Portal Knee Arthroscopy Techniques

NCT02648971

TERMINATED Early Phase 1

Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy

NCT02582008

COMPLETED NA

Effects of Strength Training on Musculoskeletal Overuse Injuries in Female Runners

NCT03080246

COMPLETED Phase 2

IN Sub-Dissociative Ketamine vs IN Fentanyl

NCT02521415

COMPLETED NA

Pre-Shave Gel and Brush in Pseudofolliculitis Barbae

NCT03043534

TERMINATED NA

The Use of Integra in Coverage of Radial Forearm Free Flap Donor Site Defect

NCT02980601

TERMINATED NA

Genomic Sequencing in Determining Treatment in Patients With Metastatic Cancer or Cancer That Cannot Be Removed by Surgery

NCT02566421

COMPLETED Phase 1

CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma

NCT02484391

TERMINATED Phase 2

LCI-NOS-PAIN-001: A Prospective, Pharmacogenomic-Driven Study of Pain Management in Oncology Outpatients

NCT02542397

TERMINATED NA

OSA Screen Negative With Spinal Duramorph

NCT03151226

COMPLETED NA

Static Magnetic Therapy for Carpal Tunnel Syndrome

NCT02609113

COMPLETED NA

Exercise Intolerance in Elderly Patients With HFpEF(Heart Failure With Preserved Ejection Fraction)

NCT02636439

← Previous Page 15 of 23 Next →

Phase Distribution

PhaseTrial count
Phase 1 96
Phase 2 143
Phase 3 31
Phase 4 80

What is open in the Wake Forest University Health Sciences pipeline

174 recruiting of 1,140 indexed (15% open); 724 completed (64%).

Phase mix: 111 late (III/IV) vs 239 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (9 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Wake Forest University Health Sciences: open-pipeline peers nationwide

Peers matched on 1,140 registered trials and 15% open enrollment, not the therapeutic-area sidebar.

Wake Forest University Health Sciences sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 8%10%12%14%16%18%20% Total trials Recruiting share Wake Forest University Health SciencesUniversity of Alabama at BirminghamNYU Langone HealthUniversity of North Carolina, Chapel HillUniversity of FloridaBaylor UniversityCornell UniversityArrowhead Regional Medical CenterAurinia Pharmaceuticals
Wake Forest University Health Sciences sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Wake Forest University Health Sciences sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,140 trials (± recruiting share)

Sponsors near 15% open enrollment (± trial volume)

What to do with this Wake Forest University Health Sciences page

1,140 registered trials is a research-attention snapshot, not an endorsement of Wake Forest University Health Sciences or any single study.

  • 174 of Wake Forest University Health Sciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Breast Cancer is the condition Wake Forest University Health Sciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Wake Forest University Health Sciences pipeline card: 1,140 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.